CAS, a division of the American Chemical Society known for its expertise in scientific knowledge management, has unveiled the CAS BioFinder Discovery Platform™. This cutting-edge life sciences platform aims to transform drug discovery by providing scientists with unparalleled insights through advanced data connections and predictive models.
The CAS BioFinder Discovery Platform is designed to expedite the early stages of drug discovery by offering a comprehensive view of both known and predicted data. This innovative tool enables researchers to quickly and reliably find answers to complex questions, significantly accelerating the pre-clinical drug discovery process.
The core of the CAS BioFinder Discovery Platform is the CAS Content Collection™, which boasts the world's most extensive and meticulously curated scientific data. The platform integrates diverse datasets, including biological sequences, structure-activity relationship data, ADME (absorption, distribution, metabolism, and excretion) measurements, and toxicity data. Recently, CAS has also added biomarker data linked to diseases and drugs, enriching the platform’s utility.
By leveraging the Chemotargets CLARITY® technology, the CAS BioFinder Discovery Platform enhances its predictive capabilities and analytics. The platform’s AI-powered technology, combined with an intuitive, visual interface, equips drug discovery scientists with tools similar to those that CAS SciFinder® has provided to chemists and related scientists for decades.
The CAS BioFinder Discovery Platform allows users to explore empirical data and utilize predictive models to gauge the likely effects of new molecules. It also offers API access to bioactivity and biomarker data, enabling scientists to process this information using their proprietary in-house models. This integration supports a holistic approach to innovation, addressing various data, research, and workflow needs.
To ensure the platform meets the most pressing needs of drug discovery scientists, CAS formed a Life Sciences Industry Advisory Board last year. This board comprises global thought leaders from commercial, academic, and government sectors, guiding CAS’s foray into life sciences. Feedback from industry partners who tested early versions of the platform has been instrumental in refining its capabilities.
The launch of the CAS BioFinder Discovery Platform marks a significant milestone in drug discovery, offering scientists a powerful new tool to drive innovation, reveal insights, and save valuable time. By combining the most comprehensive scientific data collection with state-of-the-art predictive technology, CAS is poised to revolutionize the way drug discovery is conducted, paving the way for groundbreaking advancements in the field.
Click here to read the original press release.
